Navigation Links
Orexigen(R) Therapeutics Announces Jay Hagan as Senior Vice President, Corporate Development and Strategy
Date:5/11/2009

orward-looking statements. These statements are based on the Company's current beliefs and expectations. These forward-looking statements include statements regarding the enrollment, timing and completion of clinical trials of Contrave, and the potential to obtain regulatory approval for, and effectively treat obesity with, Contrave or Empatic. The inclusion of forward-looking statements should not be regarded as a representation by Orexigen that any of its plans will be achieved. Actual results may differ from those set forth in this release due to the risk and uncertainties inherent in the Orexigen business, including, without limitation: the clinical trials of Contrave may produce negative or inconclusive results, or may be inconsistent with previously conducted clinical trials, and the FDA may not agree with the Company's interpretation of efficacy and safety results; the potential that earlier clinical trials may not be predictive of future results; Contrave may not receive regulatory approval on a timely basis or at all; the FDA may require Orexigen to complete additional clinical, non-clinical or other requirements prior to the submission or the approval of NDAs for either product candidate; the potential for adverse safety findings relating to Contrave to delay or prevent regulatory approval or commercialization, or result in product liability claims; the third parties on whom Orexigen relies to assist with the development programs for Contrave, including clinical investigators, contract laboratories, clinical research organizations and manufacturing organizations, may not successfully carry out their contractual duties or obligations or meet expected deadlines, and the quality or accuracy of the data or materials generated by such third parties may be of insufficient quality to include in the Company's regulatory submissions; the ability of Orexigen and its licensors to obtain, maintain and successfully enforce adequate patent and other intellectual prope
'/>"/>
SOURCE Orexigen Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Orexigen(R) Therapeutics to Speak at Upcoming Conferences
2. Orexigen(R) Therapeutics Announces First Quarter 2009 Financial Results
3. Orexigen(R) Therapeutics Names Michael Scaife Senior Vice President of Regulatory Affairs and Product Development, Contrave(R) Program
4. Orexigen(R) Therapeutics Schedules March 12, 2009 Webcast Discussion of Financial Results for the Fourth Quarter and Year Ended December 31, 2008
5. Orexigen(R) Therapeutics to Speak at BIO CEO & Investor Conference
6. Orexigen(R) Therapeutics Announces First of Four Phase 3 Trials of Contrave(R) Meets Co-Primary and Key Secondary Endpoints
7. Orexigen(R) Therapeutics Issued a Key Fourth U.S. Patent on Contrave(R)
8. Orexigen(R) Therapeutics Announces Third Quarter 2008 Financial Results
9. Orexigen(R) Therapeutics Initiates First Clinical Trial of OREX-003 for the Mitigation of Antipsychotic-Associated Weight Gain
10. Orexigen(R) Therapeutics Appoints Dennis Kim, M.D., as Senior Vice President, Head of Obesity and Metabolic Disorders
11. Orexigen(R) Therapeutics to Present at Upcoming Investor Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/20/2014)... August 20, 2014 The 6th ... being held on October 29-30 in San Francisco, CA. ... academic and government researchers and clinicians focused on addressing ... , In the twelve years since the sequencing ... have been introduced with pharmacogenetic information in the label ...
(Date:8/20/2014)... health of your heart, researchers have discovered. , A ... TENS machine like those designed to relieve labour pains ... raised flap at the front of the ear immediately ... changed the influence of the nervous system on the ... failing hearts too hard. , Professor Jim Deuchars, Professor ...
(Date:8/19/2014)... (PRWEB) August 20, 2014 One ... regenerative medicine is an inadequate vascular supply. Nutrient ... and decellularized tissues is critical for successful regeneration ... attempted to mitigate deficiencies in vascularization and promote ... scaffold bioactivity, optimizing scaffold design and architecture, and ...
(Date:8/19/2014)... DANVILLE, Pa. , Aug. 19, 2014 ... C has been nominated for a Centers for Disease ... to addressing a major public health concern. ... Health System, is one of a team of researchers ... (CDC) Charles C. Shepard Science Award for Data Methods ...
Breaking Biology Technology:6th Annual Personalized and Precision Medicine Conference Bringing Together Thought Leaders to Discuss Clinical Implementation, Dx Reimbursement, Big Data, and Sequencing 2'Tickling' your ear could be good for your heart 2Vascularization in Tissue Engineering Highlighted at 12th New Jersey Symposium on Biomaterials Science 2Geisinger investigator nominated for federal award 2Geisinger investigator nominated for federal award 3
... BioSpace launched the ... showcasing biotechnological, pharmaceutical and medical device companies ... (Logo: http://photos.prnewswire.com/prnh/20040907/CLTU006LOGO) (Logo: http://www.newscom.com/cgi-bin/prnh/20040907/CLTU006LOGO) ... organizations within Oregon, Washington, Idaho and Montana ...
... Ridge Diagnostics, Inc., a neurodiagnostic company, announced that ... proprietary blood test for Major Depressive Disorder (MDD)  will ... Acceptance and Utility of a Multianalyte Biomarker Panel for ... The blood test, for the first time,  provides clinicians ...
... the second year in a row, a pair of ... Manufacturing Design Competition held by the American Society of ... Casey Hoffman and Jaron Kuppers won top honors in ... Elastomeric Tooling (SET) process. The SET process offers a ...
Cached Biology Technology:BioSpace Highlights the Northwest's Growing Life Science Region 2Ridge Diagnostics, Inc. Presents Clinical Data on Blood Test for Depression at U.S. Psychiatric and Mental Health Congress 2Rensselaer mechanical engineers win first place at ASME student manufacturing design competition 2Rensselaer mechanical engineers win first place at ASME student manufacturing design competition 3Rensselaer mechanical engineers win first place at ASME student manufacturing design competition 4
(Date:8/20/2014)... Arizona State University, the Wellcome Trust Sanger Institute and ... isolated Mycobacterium pinnipedii from skeletons found in ... pathogen is a relative of the TB bacterium that ... today. These researchers assume that seals carried the pathogens ... sea lions was unexpected" comments Sebastien Gagneux, from the ...
(Date:8/20/2014)... of approximately 3 million infants, a team of scientists ... of Massachusetts Medical School, have shown that newborn screening ... across public health newborn screening programs. Data from 11 ... of the Journal of the American Medical Association ... in newborns is higher than previously thought and believed ...
(Date:8/20/2014)... the Oklahoma Medical Research Foundation a five-year, $14.5 million ... bacteria,s effects on humans. , For 10 years, ... studied the human immune response to anthrax bacteria as ... original funding came soon after anthrax-laced letters killed five ... attacks of Sept. 11, 2001. , The long-term ...
Breaking Biology News(10 mins):Newborn screening expansion offers early diagnosis and treatment to infants with SCID 2Newborn screening expansion offers early diagnosis and treatment to infants with SCID 3$14.5 million grant awarded to continue anthrax studies 2
... do undergraduate students gain valuable hands-on experience by participating ... contributions, examples of which are highlighted in the current ... a peer-reviewed journal published by Mary Ann Liebert, Inc. ... This special issue features a collection of papers ...
... Scientists at The Scripps Research Institute have designed a new ... drugs targeting a human metabolic enzyme believed to stimulate the ... new test, which the scientists call a simple assay, will ... for those that have potential to block the action of ...
... LA JOLLA, CA September 16, 2010 For Immediate ... been awarded a four-year, $5.1 million grant as part of ... development of the next generation of DNA sequencing technologies, which ... sequence a person,s DNA. With the new grant, ...
Cached Biology News:Undergraduate research highlighted in DNA and Cell Biology Journal 2Scripps scientists develop test providing new pathway for identifying obesity, diabetes drugs 2Scripps scientists develop test providing new pathway for identifying obesity, diabetes drugs 3Scripps research team wins $5.1 million to develop DNA sequencing technology 2
...
... series of microplate readers combines reagent dispensing ... an affordable, easy-to-use platform for the complete ... modular design and adaptability of the Infinite ... of a monochromator (M200) or filter (F200) ...
... Lines ,High Quality, Functionally-Validated, Ion Channel Cell ... for having a critical role in nerve ... key function in pain, CNS and the ... been investigated in therapeutic areas, such as ...
Mouse monoclonal antibody raised against a partial recombinant ARHGEF11. NCBI Entrez Gene ID = ARHGEF11...
Biology Products: